天津医药 ›› 2021, Vol. 49 ›› Issue (1): 32-35.doi: 10.11958/20202137

• 临床研究 • 上一篇    下一篇

托珠单抗和硫唑嘌呤对NMOSD患者视神经炎后视神经变化的影响#br#

杨俊峰1,曾培1,杜琛1,江枫2,张瑞1,李晓文1,张超1,王春阳1,3△   

  1. 1天津医科大学总医院神经内科(邮编300052),2眼科,3科研处
  • 收稿日期:2020-07-27 修回日期:2020-10-09 出版日期:2021-01-15 发布日期:2021-03-12
  • 通讯作者: 王春阳 E-mail:cwang@tmu.edu.cn
  • 基金资助:
    国家自然科学基金青年基金项目(81601019,81800853);天津市科学技术局青年科学基金项目(18JCQNJC13200);吴阶平医学基金会临床科研专项资助基金(320.6750.19089-56)

Effects of tocilizumab and azathioprine on the changes of optic nerve after optic neuritis in NMOSD patients#br#

YANG Jun-feng1, ZENG Pei1, DU Chen1, JIANG Feng2, ZHANG Rui1, LI Xiao-wen1, ZHANG Chao1, WANG Chun-yang1, 3△   

  1. 1 Department of Neurology, 2 Department of Ophthalmology, 3 Academic Research Department, Tianjin 
    Medical University General Hospital, Tianjin 300052, China
  • Received:2020-07-27 Revised:2020-10-09 Published:2021-01-15 Online:2021-03-12

摘要: 摘要:目的 比较托珠单抗和硫唑嘌呤对视神经脊髓炎谱系疾病(NMOSD)视神经炎(ON)后视觉功能系统变化的影响。方法 回顾性分析天津医科大学总医院神经内科收治的NMOSD患者67例,其中托珠单抗组33例,受累眼42只;硫唑嘌呤组34例,受累眼44只。采用视力表、光学相干断层显像、视觉诱发电位(VEP)检测并比较2组受累眼视力、黄斑区视神经节细胞复合体(GCC)厚度、视乳头周围视网膜神经纤维层厚度(pRNFL)、VEP P100波幅和潜伏期在随访1年前后的变化以及2组之间对应指标的差异。结果 与用药前相比,用药后托珠单抗和硫唑嘌呤组患者受累眼的最小分辨角对数(LogMAR)视力和低对比度视力均未发生明显变化,但2组患者受累眼黄斑区GCC、视乳头周围pRNFL厚度均变薄,VEP P100波幅均降低(P<0.05),硫唑嘌呤组患者VEP P100潜伏期延长(P<0.01),硫唑嘌呤组VEP P100波幅降低幅度较托珠单抗组大(P<0.05)。结论 托珠单抗和硫唑嘌呤均不能逆转NMOSD患者ON后受累眼视神经变性萎缩的过程。但与硫唑嘌呤相比,托珠单抗可能有助于延缓视神经轴索变性。

关键词: 视神经脊髓炎;视神经炎;硫唑嘌呤;视网膜神经节细胞;黄斑;诱发电位, 视觉;体层摄影术, 光学相干;托珠单抗

Abstract:

Abstract: Objective To compare the effects of tocilizumab and azathioprine on the visual function after optic neuritis (ON) in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods Data of 67 NMOSD patients treated in Tianjin Medical University General Hospital were retrospectively analyzed. There were 33 patients (42 eyes) received treatment of tocilizumab and 34 patients (44 eyes) received treatment of azathioprine. The visual acuity chart, optical coherence tomography and visual evoked potential (VEP) were used to detect changes of visual acuity, macular optic ganglion cell complex (GCC) thickness, peripapillary retinal nerve fiber layer (pRNFL) thickness and VEP P100 amplitude and latency from baseline in the two groups. Results There were no significant differences in the Logarithm of the minimum angle of resolution (LogMAR) visual acuity and low-contrast visual acuity between baseline and after treatment with tozumab and azathioprine, while the thickness of macular GCC and peripapillary pRNFL were thinner, and VEP P100 amplitude reduced in the both groups (P<0.05). The latency of VEP P100 was prolonged in azathioprine group (P<0.01). Compared with the tozumab group, the amplitude of VEP P100 was significantly lower in the azathioprine group (P<0.05). Conclusion Neither tocilizumab nor azathioprine can reverse the process of optic nerve degeneration and atrophy after optic neuritis in NMOSD patients. However, compared with azathioprine, tocilizumab may help delay optic axonal degeneration.

Key words: neuromyelitis optica, optic neuritis, azathioprine, retinal ganglion cells, macula lutea, evoked potentials, visual, tomography, optical coherence, tocilizumab